Simon Powell

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells
    Ranjit S Bindra
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nucleic Acids Res 41:e115. 2013
  2. doi request reprint Radiotherapy for breast cancer in the 21st Century
    Simon Powell
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Breast J 16:S34-8. 2010
  3. doi request reprint Targeting the DNA damage response for cancer therapy
    Simon N Powell
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    DNA Repair (Amst) 8:1153-65. 2009
  4. doi request reprint Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment
    Sarah Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3762-70. 2012
  5. doi request reprint Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:1994-2003. 2012
  6. ncbi request reprint Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer
    Zachary S Zumsteg
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:3469-76. 2013
  7. doi request reprint Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation
    Alice Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:2552-9. 2012
  8. doi request reprint Patterns of utilization of adjuvant radiotherapy and outcomes in black women after breast conservation at a large multidisciplinary cancer center
    Sophia M Edwards-Bennett
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 80:1102-8. 2011
  9. doi request reprint Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy
    Shannon M Macdonald
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 75:1297-303. 2009
  10. ncbi request reprint Therapeutic exploitation of tumor cell defects in homologous recombination
    Simon N Powell
    Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park, St Louis, MO 63108, USA
    Anticancer Agents Med Chem 8:448-60. 2008

Collaborators

Detail Information

Publications25

  1. pmc Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells
    Ranjit S Bindra
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nucleic Acids Res 41:e115. 2013
    ..Collectively, the novel DSB repair assay and inducible I-SceI will be useful tools to further elucidate the complexities of NHEJ and HR repair...
  2. doi request reprint Radiotherapy for breast cancer in the 21st Century
    Simon Powell
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Breast J 16:S34-8. 2010
    ..Biological enhancement of the effect of radiotherapy could allow dose reduction, with presumed reductions in the toxicity of treatment. In conclusion, breast cancer radiotherapy has much to understand and optimize in the 21st Century...
  3. doi request reprint Targeting the DNA damage response for cancer therapy
    Simon N Powell
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
    DNA Repair (Amst) 8:1153-65. 2009
    ..As these defects are specific to tumor cells, the development of new anti-cancer agents targeting these pathways may have an enhanced therapeutic window, with limited normal tissue toxicity...
  4. doi request reprint Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment
    Sarah Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3762-70. 2012
    ..Our aims were to evaluate the characteristics and outcomes of SLNB-positive TM patients who did not receive axillary-specific treatment and to compare them to similar patients who underwent breast-conserving surgery (BCS)...
  5. doi request reprint Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 118:1994-2003. 2012
    ..The additional value of axillary radiotherapy in these patients is unknown...
  6. ncbi request reprint Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer
    Zachary S Zumsteg
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:3469-76. 2013
    ..Conflicting data exist regarding optimum local therapy for early-stage triple-negative breast cancer (TNBC). We examined outcomes according to local treatment type in a large cohort of node-negative TNBC patients...
  7. doi request reprint Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation
    Alice Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:2552-9. 2012
    ..The long-term rates of permanent implant removal or replacement (PIRR) and clinical outcomes in patients treated with a uniform reconstructive surgery and radiation regimen were evaluated...
  8. doi request reprint Patterns of utilization of adjuvant radiotherapy and outcomes in black women after breast conservation at a large multidisciplinary cancer center
    Sophia M Edwards-Bennett
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 80:1102-8. 2011
    ....
  9. doi request reprint Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy
    Shannon M Macdonald
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 75:1297-303. 2009
    ....
  10. ncbi request reprint Therapeutic exploitation of tumor cell defects in homologous recombination
    Simon N Powell
    Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park, St Louis, MO 63108, USA
    Anticancer Agents Med Chem 8:448-60. 2008
    ..Thus, functional assays of homologous recombination could become a useful technique to determine phenotype of human breast cancer, which in turn will influence the choice of therapy...
  11. ncbi request reprint ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining
    Hongyan Wang
    Department of Radiation Oncology, Kimmel Cancer Center of Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 64:7139-43. 2004
    ..These results indicate that the effects of ATR on cell radiosensitivity are independent of NHEJ but are linked to HRR that may be affected by the deficient S and G(2) checkpoints...
  12. ncbi request reprint The role of the BRCA1 tumor suppressor in DNA double-strand break repair
    Junran Zhang
    Department of Radiation Oncology, Washington University in St Louis, 4511 Forest Park Boulevard, St Louis, Missouri 63108, USA
    Mol Cancer Res 3:531-9. 2005
    ..Finally, we will explore the idea that tumor suppression by BRCA1 depends on its control of DNA DSB repair, resulting in the promotion of error-free and the inhibition of error-prone recombinational repair...
  13. ncbi request reprint MDC1 interacts with Rad51 and facilitates homologous recombination
    Junran Zhang
    Department of Radiation Oncology, MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Struct Mol Biol 12:902-9. 2005
    ..Together, our findings suggest that MDC1 functions in Rad51-mediated homologous recombination by retaining Rad51 in chromatin...
  14. pmc Mammalian Rad9 plays a role in telomere stability, S- and G2-phase-specific cell survival, and homologous recombinational repair
    Raj K Pandita
    Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park Ave, St Louis, MO 63108, USA
    Mol Cell Biol 26:1850-64. 2006
    ..Together, these findings provide evidence of roles for mammalian Rad9 in telomere stability and HR repair as a mechanism for promoting cell survival after IR exposure...
  15. doi request reprint The effect of age in the outcome and treatment of older women with ductal carcinoma in situ
    Alice Ho
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Breast 20:71-7. 2011
    ..00001) but not age. It is possible to identify older women with DCIS in whom the risk of recurrence is acceptably low after WLE alone. WLE alone may be a viable treatment option for select older women with DCIS...
  16. doi request reprint Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation
    Wei Shi
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri 63108, USA
    J Biol Chem 283:31608-16. 2008
    ..Collectively, the evidence presented here supports a novel mechanism for the disassembly of MDC1 foci via ubiquitin-proteasome dependent degradation, which appears to be a key step for the efficient assembly of BRCA1 foci...
  17. doi request reprint Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies
    Henning Willers
    Laboratory of Cellular and Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA
    Mol Cancer Res 7:1304-9. 2009
    ....
  18. ncbi request reprint DNA damage induces p53-dependent BRCA1 nuclear export
    Zhihui Feng
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    J Biol Chem 279:28574-84. 2004
    ..These results imply that, in addition to ATM-, ATR-, and Chk2-dependent phosphorylations, cytoplasmic relocalization of BRCA1 protein is a mechanism whereby BRCA1 function is regulated in response to DNA damage...
  19. doi request reprint Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells
    James W Evans
    Department of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University, Stanford, California 94305 5152, USA
    Cancer Res 68:257-65. 2008
    ....
  20. pmc Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair
    Junran Zhang
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA
    Mol Cell Biol 24:708-18. 2004
    ..We propose a dual regulatory role for BRCA1 in maintaining genome integrity, whereby BRCA1 phosphorylation status controls the selectivity of repair events dictated by HR and error-prone NHR...
  21. ncbi request reprint Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining
    Jing Zhuang
    Department of Radiation Oncology, Vanderbilt University Medical Centre, 1301 22nd Avenue South, Nashville, TN 37232, USA
    Cancer Res 66:1401-8. 2006
    ..We suggest that the differential control of NHEJ subprocesses by BRCA1, in concert with Chk2, reduces the mutagenic potential of NHEJ, thereby contributing to the prevention of familial breast cancers...
  22. pmc The role of RPA2 phosphorylation in homologous recombination in response to replication arrest
    Wei Shi
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63108, USA
    Carcinogenesis 31:994-1002. 2010
    ..Thus, our data suggest that RPA2 hyperphosphorylation plays a critical role in maintenance of genomic stability and cell survival after a DNA replication block via promotion of HR...
  23. pmc Negative Regulation of AKT Activation by BRCA1
    Tao Xiang
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Cancer Res 68:10040-4. 2008
    ..Our results show that BRCA1 is a negative regulator of the AKT pathway and imply the significance of the BRCA1/AKT pathway in tumorigenesis...
  24. ncbi request reprint BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II
    Alejandro D Treszezamsky
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Cancer Res 67:7078-81. 2007
    ..Overall, these results suggest that etoposide is a potentially useful drug in the treatment of BRCA-deficient human cancers...
  25. ncbi request reprint Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation
    Simon N Powell
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Oncogene 22:5784-91. 2003
    ..The unsolved mystery is the other genetic changes that must occur to turn a BRCA-deficient cell from a nonviable cell into a tumor cell capable of endless growth...

Research Grants25

  1. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2004
    ....
  2. Roles of BRCA1, BRCA2 in Homologous Recombination
    Simon Powell; Fiscal Year: 2004
    ..Ultimately, the defects in HR that promote carcinogenesis by causing genetic instability may also offer a novel therapeutic target against the cancers that arise in this setting. ..
  3. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2005
    ....
  4. Roles of BRCA1, BRCA2 in Homologous Recombination
    Simon Powell; Fiscal Year: 2005
    ..Ultimately, the defects in HR that promote carcinogenesis by causing genetic instability may also offer a novel therapeutic target against the cancers that arise in this setting. ..
  5. Roles of BRCA1, BRCA2 in Homologous Recombination
    Simon Powell; Fiscal Year: 2006
    ..Ultimately, the defects in HR that promote carcinogenesis by causing genetic instability may also offer a novel therapeutic target against the cancers that arise in this setting. ..
  6. Roles of BRCA1, BRCA2 in Homologous Recombination
    Simon Powell; Fiscal Year: 2005
    ..Ultimately, the defects in HR that promote carcinogenesis by causing genetic instability may also offer a novel therapeutic target against the cancers that arise in this setting. ..
  7. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2005
    ....
  8. DNA Recombinational Repair: Role of the p53 Tumor Suppressor Protein
    Simon Powell; Fiscal Year: 2006
    ....
  9. Roles of BRCA1, BRCA2 in Homologous Recombination
    Simon Powell; Fiscal Year: 2007
    ..Ultimately, the defects in HR that promote carcinogenesis by causing genetic instability may also offer a novel therapeutic target against the cancers that arise in this setting. ..
  10. DNA Recombinational Repair: Role of the p53 Tumor Suppressor Protein
    Simon Powell; Fiscal Year: 2009
    ....
  11. AT: ERRORS IN DOUBLE STRAND BREAK REPAIR
    Simon Powell; Fiscal Year: 2003
    ..Functional analysis will address the relationship between the NBS- containing protein complex and ATM in a DNA damage response pathway. ..
  12. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2003
    ....
  13. AT: ERRORS IN DOUBLE STRAND BREAK REPAIR
    Simon Powell; Fiscal Year: 2002
    ..Functional analysis will address the relationship between the NBS- containing protein complex and ATM in a DNA damage response pathway. ..
  14. DNA RECOMBINATION AND RADIATION RESISTANCE
    Simon Powell; Fiscal Year: 1999
    ....
  15. DNA RECOMBINATION AND RADIATION RESISTANCE
    Simon Powell; Fiscal Year: 1992
    ..A spectrum of clinical radiosensitivity will also be assessed...
  16. DNA RECOMBINATION AND RADIATION RESISTANCE
    Simon Powell; Fiscal Year: 1993
    ..A spectrum of clinical radiosensitivity will also be assessed...
  17. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2001
    ....
  18. AT: ERRORS IN DOUBLE STRAND BREAK REPAIR
    Simon Powell; Fiscal Year: 2001
    ..Functional analysis will address the relationship between the NBS- containing protein complex and ATM in a DNA damage response pathway. ..
  19. DNA REPAIR--ROLE OF THE P53 TUMOR SUPPRESSOR PROTEIN
    Simon Powell; Fiscal Year: 2002
    ....
  20. DNA Recombinational Repair: Role of the p53 Tumor Suppressor Protein
    Simon N Powell; Fiscal Year: 2010
    ....
  21. AT: ERRORS IN DOUBLE STRAND BREAK REPAIR
    Simon Powell; Fiscal Year: 2000
    ..Functional analysis will address the relationship between the NBS- containing protein complex and ATM in a DNA damage response pathway. ..